Sigilon Therapeutics Inc (SGTX) 시세

He made NOTHING.

SGTX: Because NO ONE on the entire iHub PLATFORM owned any of this Firm's shares yesterday --- nor for months!!! (Including glorious Mr. EZBucks chap.) And THAT is why, Bro.

Hey, Admiral Scotty, Mr. EZ did NOT have even one share of this Beast --- since he "alerted it" MONTHS ago. (However, just imagine the Peeps that DID own this yesterday; and, when one reads the Lily DEAL, they gots lots MORE CASH coming, no matter how that Investigation goes down!!!!)

PS: My 'CONGRATS' post to Mr. EZ was pure SARCASM!!! (I used to like that dude, but he's just jerk.)

SGTX: Well, King EZ --- since you must have grabbed a huge chunk of this at a paltry $0.66 months ago --- you surely must have dumped it all today for well over ONE-MILLION-DOLLARS profit!!! WOW, Dude!!! MONSTER CONGRATS to ya, Emperor EZ!!!!!

SGTX LIKE********THINKIN OF ***LXRX**WINT***GNPX****SLS***ORTX****PROBABLE ACQUISITION CANDIDATE. WHAT DO YOU THINK. THANKS

I KNOW YOU ALAWYS SHARE, KINDLY DO NOT LEAVE US ON THE SIDELINE. THANK YOU ALWAYS

This is huge news, why is no one talking about??

Why don’t you set up an alert service? There are plenty you can use that all you need to do is charge a nominal sum and then you can alert your entries with any other comments you want to add in real time.

SGTX "Nothing to see here"- already happened - but can marvel at :)

SIGILON THERAPEUTICS INC
$24.75 +20.82 (+529.77%)
As of Jun-29-2023

Sigilon Therapeutics Shares Are Shooting Higher Today - What's Going On
by BENZINGA

Sigilon Therapeutics Inc (NASDAQ:SGTX) shares are skyrocketing after Eli Lilly And Co (NYSE:LLY) agreed to acquire the company for a purchase price of $14.92 per share in cash (an aggregate of approximately $34.6 million).

Sigilon is also entitled to one non-tradeable contingent value right ("CVR") per share to receive up to an additional $111.64 per share in cash, for a total potential consideration of up to $126.56 per share in cash without interest (an aggregate of up to approximately $309.6 million excluding shares held by Lilly).

The transaction is not subject to any financing condition and is expected to close in the third quarter of 2023.

Since 2018, Lilly and Sigilon have worked together to develop encapsulated cell therapies, including SIG-002, for type 1 diabetes.

In the Q1 FY23 earnings release, Sigilon said its near-term focus is on development efforts for SIG-002, its product candidate for type 1 diabetes, which is being developed in collaboration with Eli Lilly.

Sigilon initiated IND-enabling activities for SIG-002 and anticipates initiating non-human primate (NHP) studies in 2H 2023. Additionally, the company expects an IND submission for SIG-002 in 2024.

$SGTX: Thanx dude.....................

Appreciate the KIND words.


Lots more to be made on the markets.......... got my eyes on more diamonds in the rough.

This isn't the only one


GO $SGTX

MAKINEZ, HOPE YOU BANK BIG! CONGRATS

DIAMOND IN A ROUGH COMES ONCE IN WHILE, THIS IS DEFINITELY ONE.
DANCING TO THE BANK AND GOOD FOR THE PUBLIC TOO.
NEW DRUG IS COMING TO THE MARKET PRETTY SOON

$SGTX: Gave it to you at $0.66 .... NOW $36 !!!!!!!!!!!!!


YEEEEEEEOWWwwwwwwwwwwwwwwwwwwwwwww...................... Y'all MAKIN EZ MONEY YET ???


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171441550


GO $SGTX

Hope you made some $$$

Lilly to Acquire Sigilon Therapeutics

$SGTX: Killer intraday mover........... from $0.74..........

And now $1.30 !!!!!!!!!!



YEEEEEEEEeeeowwwwwwwwwwwwwwwwwwwww........................ I'm running out of POSTS..


Where my loyal followers........... I've been giving you bangers lately,

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171438110


Hook me up with a ONE YEAR iHUB sub amigos.


GO $SGTX

sgtx the next bio to soar...1.25 coming here

$SGTX: MarketCap only $11Milly.... Cash-on-HAND at $96Milly

I would say this can go up another $2share from here for sure.


Now at 0.66


GO $SGTX

$SGTX: Is it too late ?? now 0.70

Wish I saw this a lil earlier.


But nice pop there....................


https://ir.sigilon.com/static-files/94cc6b3f-5656-497a-a9be-0e8b4d1c1b36


GO $SGTX

HERE WE GO

SGTX ON THE MOVE

Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the pricing of its upsized initial public offering of 7,000,000 shares of its common stock at a public offering price of $18.00 per share. All of the shares are being offered by Sigilon. In addition, Sigilon has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Sigilon’s common stock is expected to begin trading on the Nasdaq Global Market on December 4, 2020 under the symbol “SGTX.”
The gross proceeds of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Sigilon, are expected to be $126.0 million excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on December 8, 2020, subject to the satisfaction of customary closing conditions.

Sigilon Therapeutics Inc. is a clinical-stage biotechnology company seeking to develop functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules to patients. The Company has developed its SLTx platform, which combines advanced cell engineering with advancements in biocompatible materials and enables its product candidates to produce a wide range of therapeutic molecules that may be missing or deficient, such as proteins, antibodies and enzymes. The Company’s lead product candidate is SIG-001, which is designed to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia. The Company’s other product candidates includes SIG-009, SIG-003, SIG-005, SIG-007, SIG-018, SIG-002, SIG-014 and SIG-015.

IPO > closing price > 34.78